Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 04:08 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Islet Allotransplantation in Type 1 Diabetes
NCT01705899 · Ohio State University · PHASE1 · suspended · last registry update 2025-01-16 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Pausing of allotransplant program due to logistic issues.” | – | Registry record, Ohio State University |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IL2RA within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-01-15Also stopped (withdrawn): Camillo Ricordi and Jay Skyler, Anti-Thymocyte Globulin (ATG) + Interleukin 2 (NCT02586831)
- 2026-01-13Results posted on the registry: Beth Israel Deaconess Medical Center, Interleukin-2 (NCT02739412)
- 2025-12-24Also stopped (withdrawn): City of Hope Medical Center, Aldesleukin + Cyclophosphamide (NCT06626256)
- 2025-12-19Results posted on the registry: National Cancer Institute (NCI), Aldesleukin + Cyclophosphamide (NCT01319565)
- 2025-12-16Results posted on the registry: Fady M Kaldas, M.D., F.A.C.S., Basiliximab 20 MG (NCT04104438)
- 2025-12-08Results posted on the registry: University of Washington, Aldesleukin + Pembrolizumab (NCT03260504)
- 2025-12-08Also stopped (terminated): University of Washington, Aldesleukin + Pembrolizumab (NCT03260504)
- 2025-12-02Results posted on the registry: National Cancer Institute (NCI), IL-2 (Aldesleukin) + Cyclophosphamide (NCT05035407)
- 2025-12-02Also stopped (terminated): National Cancer Institute (NCI), IL-2 (Aldesleukin) + Cyclophosphamide (NCT05035407)
- 2025-11-10Results posted on the registry: Alaunos Therapeutics, Neoantigen specific TCR-T cell drug product + Aldesleukin (IL-2) (NCT05194735)
- 2025-11-10Also stopped (terminated): University of Southern California, Twice-daily Tacrolimus + Once-daily envarsus XR (NCT04773392)
- 2025-09-22Also stopped (terminated): Vall d'Hebron Institute of Oncology, Cyclophosphamide + Trastuzumab (NCT05385705)
- 2025-09-11Also stopped (withdrawn): National Cancer Institute (NCI), KRAS TCR-Transduced PBL + Aldesleukin (NCT06690281)
- 2025-07-10Phase 3 first posted: Shanxi Bethune Hospital, Induction Therapy Regimen + Pre-Treatment Regimen (NCT07059156)
- 2025-06-05Also stopped (withdrawn): James Isaacs, MD, LN-144 + Cyclophosphamide (NCT06190249)
- 2025-04-30Also stopped (suspended): Indapta Therapeutics, INC., IDP-023 + Ocrelizumab (NCT06677710)
- 2025-01-15Results posted on the registry: M.D. Anderson Cancer Center, Aldesleukin + Cyclophosphamide (NCT02500576)
- 2025-01-07Also stopped (terminated): Dompé Farmaceutici S.p.A, Reparixin (NCT03031470)
- 2024-12-12Also stopped (terminated): Celularity Incorporated, CYNK-001 (NCT04310592)
- 2024-12-12Also stopped (terminated): Celularity Incorporated, CYNK-101 + Pembrolizumab (NCT05207722)
- 2024-12-11Results posted on the registry: Dompé Farmaceutici S.p.A, Reparixin (NCT03031470)
- 2024-12-03Results posted on the registry: National Heart, Lung, and Blood Institute (NHLBI), cell infusion (NCT03354390)
- 2024-11-22Results posted on the registry: Inge Marie Svane, Cyclophosphamide + Fludarabine (NCT02926053)
- 2024-11-07Results posted on the registry: M.D. Anderson Cancer Center, Aldesleukin + CD8-Positive T-Lymphocyte (NCT03318900)
- 2024-10-26Results posted on the registry: Inge Marie Svane, Autologous tumor-infiltrating lymphocytes + Ipilimumab (NCT03296137)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision